Mikkael Sekeres, MD @MikkaelSekeres of Cleveland Clinic @ClevelandClinic discusses the phase II study of pevonedistat + azacitidine vs. A in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia presented at this year’s virtual ASCO.
Mikkael Sekeres, MD on Phase II Study of Pevonedistat + Azacitidine in MDS/CMML or AML @MikkaelSekeres #ASCO @ClevelandCinic #ASCO2020
